Divi's Laboratories Q3 net profit up 64.5% to ₹589 crore, revenue rises 25%

Revenue from operations surged 25% to ₹2,319 crore in the third quarter of the financial year 2024-25, compared to ₹1,855 crore a year back.

EBITDA (Earnings before interest, taxes, depreciation and amortisation) rose 52% to ₹743 crore in the latest October-December quarter as compared to ₹489 crore in Q3 FY24. The EBITDA margin was at 32% vs 26.4% in the same period the previous year.

Divi's Lab share price

Shares of Divi's Laboratories were trading 3.85% higher at ₹5,834.85 apiece on the National Stock Exchange (NSE) at 1:32 pm.

"For the current quarter, we have forex gain of ₹10 crore as against a gain of ₹18 crore during the corresponding quarter of the previous year," the company said in a regulatory filing.

How did Divi's Lab perform in 9M FY25?

For the nine months ended December 31, 2024, the pharma major reported a 43.97% jump in net profit to ₹1,529 crore, as against ₹1,062 crore in the same period a year ago.

In 9M FY25, "The company earned a consolidated total income of ₹7,041 crore as against a consolidated total income of ₹5,804 crore during the corresponding nine months period of the previous year. PBT for the current nine months period accounted to ₹2,052 crore as against ₹1,450 crore for the corresponding nine months period of the previous year," Divi's Lab said.

The company's Kakinada Project (Unit-III) also commenced commercial operations from January 1, 2025. "We have capitalised assets of ₹433 crore for the quarter and of ₹557 crore for the 9-month period of the current year. Of this, capitalisation for Kakinada Project is ₹418 crore during the 9-month period," the firm said.